Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2016

01-04-2016 | Gynecologic Cancers (NS Reed, Section Editor)

Lymphovascular Space Invasion as a Risk Factor in Early Endometrial Cancer

Authors: Azmat H. Sadozye, Rosie L. Harrand, Nick S. Reed

Published in: Current Oncology Reports | Issue 4/2016

Login to get access

Abstract

Management of early endometrial cancer is contentious these days with little agreement between oncologists as well as across MDTs or tumour boards and indeed across countries. This is because of the state of knowledge with regards to risk factors in early endometrial cancer; although we recognise risk factors affect outcome, we haven’t yet been able to demonstrate that our treatments make a significant difference. We have reviewed available literature on LVSI and are able to demonstrate that it is an independent risk factor for nodal metastasis as well as distant recurrence. We need a randomised trial integrating grade and LVSI and testing therapeutic options of radiotherapy and chemotherapy. However, it is unlikely to see the light of day. Therefore, we are left with this knowledge of prognostic factors and it is our duty to integrate this into our decision-making during our multidisciplinary team meetings and make decisions tailored to individual patient circumstances.
Literature
1.
Nout RA, van de Poll-Franse LV, Lybeert MLM, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JWM, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) Trial. J Clin Oncol. 2011;29:1692–700.CrossRefPubMed
2.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed
3.
Nout RA, Smit VTHBM, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed
4.
Lee CM, Szabo A, Shrieve DC, Macdonald OK, Gaffney DK. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA. 2006;295:389–97.CrossRefPubMed
5.
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31.CrossRefPubMedPubMedCentral
6.
Cohn DE, Horowitz NS, Mutch DG, Kim S-M, Manolitsas T, Fowler JM. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol. 2002;87:243–6.CrossRefPubMed
7.
Briet JM, Hollema H, Reesink N, Aalders JG, Mourits MJE, ten Hoor KA, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96:799–804.CrossRefPubMed
8.•
Koskas M, Bassot K, Graesslin O, Aristizabal P, Barranger E, Clavel-Chapelon F, et al. Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer. Gynecol Oncol. 2013;129:292–7. Presence of LVSI was associated with higher grade tumours, more than 50% myometrial invasion, cervical involvement and nodal spread.
9.
Narayan K, Khaw P, Bernshaw D, Mileshkin L, Kondalsamy-Chennakesavan S. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy. Int J Gynecol Cancer. 2012;22:260–6.CrossRefPubMed
10.•
Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012;124:31–5. LVSI (OR 6.34) and deep myometrial invasion (OR 4.9) were strong predictors for node positivity.
11.
Cheewakriangkrai C, Panggid K, Siriaungkul S, Khunamornpong S, Suprasert P, Srisomboon J. Lymphovascular space invasion as a prognostic determinant in uterine cancer. Asian Pac J Cancer Prev. 2007;8:363–6.PubMed
12.•
Bosse T, Peters EEM, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JWM, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51:1742–50. In a multivariate analysis, (including: age, depth of myometrial invasion, grade, treatment) substantial LVSI remained the strongest independent prognostic factor for pelvic regional recurrence (HR 6.2 CI 2.4–16).
13.
Zhang GY, Wu LY, Li B, Huang MN, Zhang R, Li XG. Retrospective analysis of prognostic variables and clinical outcomes in surgically staged intermediate risk endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):309–16.CrossRefPubMed
14.
Zhang C, Wang C, Feng W. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer. 2012;22:1373–7.CrossRefPubMed
15.
Ho-Suap HAHN, In-Ho LEE, Tae-Jin KIM, Ki-Heon LEE, Jae-Uk SHIM, Jae-Wook KIM, et al. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer. Aust N Z J Obstet Gynaecol. 2013;53:293–7.CrossRef
16.
Boren T, Lea J, Kehoe S, Miller DS, Richardson D. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012;127(1):43–6.CrossRefPubMed
17.
Akbayir O, Corbacioglu A, Goksedef BP, Numanoglu C, Akca A, Guraslan H, et al. The novel criteria for predicting pelvic lymph node metastasis in endometrioid adenocarcinoma of endometrium. Gynecol Oncol. 2012;125(2):400–3.CrossRefPubMed
18.
Chang SJ, Kong TW, Kim WY, Yoo SC, Yoon JH, Chang KH, et al. Lymph-vascular space invasion as a significant risk factor for isolated para-aortic lymph node metastasis in endometrial cancer: a study of 203 consecutive patients. Ann Surg Oncol. 2011;18(1):58–64.CrossRefPubMed
19.
Hachisuga T, Kaku T, Fukuda K, Eguchi F, Emoto M, Kamura T, et al. The grading of lymphovascular space invasion in endometrial carcinoma. Cancer. 1999;86(10):2090–7.CrossRefPubMed
20.
Vaizoglu F, Yuce K, Salman MC, Basaran D, Calis P, Ozgul N, et al. Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer. Arch Gynecol Obstet. 2013;288(6):1391–7.CrossRefPubMed
21.
Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol. 2005;96:651–7.CrossRefPubMed
22.
Nofech-Mozes S, Ackerman I, Ghorab Z, Thomas NIG, Covens A, Khalifa MA. Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 2008;129:912–7.CrossRefPubMed
23.
Gadducci A, Cavazzana A, Cosio S, di Cristofano C, Tana R, Fanucchi A, et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res. 2009;29:1715–20.PubMed
24.
O’Brien DJ, Flannelly G, Mooney EE, Foleya M. Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality. BJOG. 2009;116:991–4.CrossRefPubMed
25.
Puljiz M, Puljiz Ž, Danolić D, Alvir I, Tomica D, Mamić I, et al. Prognostic value of lymphovascular space invasion in endometrial cancer. Med Glas. 2013;10(2):288–92.
26.
Alexander-Sefre F, Singh N, Ayhan A, Thomas JM, Jacobs IJ. Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer. Gynecol Oncol. 2004;92:653–9.CrossRefPubMed
27.
Lim S, Lee K-B, Park C-Y. The prognostic significance of lymphovascular space involvement in patients with uterine confined endometrioid endometrial cancer. Korean J Obstet Gynecol. 2012;55(2):76–82.CrossRef
28.
Song T, Lee JW, Choi CH, Kim TJ, Bae DS, Sung CO, et al. Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer. Int J Clin Oncol. 2012;17(6):590–7.CrossRefPubMed
29.
Mariani A, Dowdy SC, Keeney GL, Haddock MG, Lesnick TG, Podratz KC. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005;97:820–7.CrossRefPubMed
30.
Simpkins F, Papadia A, Kunos C, Michener C, Frasure H, AbuShahin F, et al. Patterns of recurrence in stage i endometrioid endometrial adenocarcinoma with lymphovascular space invasion. Int J Gynecol Cancer. 2013;23:98–104.CrossRefPubMed
31.
Gadducci A, Cosio S, Fabrini MG, Fanucchi A, Barsotti C, Cristofani R, et al. Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. Anticancer Res. 2011;31(10):3483–8.PubMed
32.
Panggid K, Cheewakriangkrai C, Khunamornpong S, Siriaunkgul S. Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res. 2010;36(5):1044–8.CrossRefPubMed
33.
Vandenput I, Vanhove T, Calster BV, Gorp TV, Moerman P, Verbist G, et al. The use of lymph vessel markers to predict endometrial cancer outcome. Int J Gynecol Cancer. 2010;20(3):363–7.CrossRefPubMed
34.
Gemer O, Ben Arie A, Levy T, Gdalevich M, Lorian M, Barak F, et al. Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. Eur J Surg Oncol. 2007;33:644–7.CrossRefPubMed
35.
Loizzi V, Cormio G, Lorusso M, Latorre D, Falagario M, Demitri P, et al. The impact of lymphvascular space invasion on recurrence and survival in patients with early stage endometrial cancer. Eur J Cancer Care. 2014;23(3):380–4.CrossRef
36.
Aristizabal P, Graesslin O, Barranger E, Clavel-Chapelon F, Haddad B, Luton D, et al. A suggested modification to FIGO stage I endometrial cancer. Gynecol Oncol. 2014;133(2):192–6.CrossRefPubMed
37.
Weinberg LE, Kunos CA, Zanotti KM. Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer. Int J Gynecol Cancer. 2013;23(8):1438–45.CrossRefPubMed
38.
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(21):1625–34.CrossRefPubMed
Metadata
Title
Lymphovascular Space Invasion as a Risk Factor in Early Endometrial Cancer
Authors
Azmat H. Sadozye
Rosie L. Harrand
Nick S. Reed
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-016-0505-1

Other articles of this Issue 4/2016

Current Oncology Reports 4/2016 Go to the issue

Cardio-oncology (EH Yang, Section Editor)

Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future

Gynecologic Cancers (NS Reed, Section Editor)

Brachytherapy in Gynecologic Cancers: Why Is It Underused?

Gynecologic Cancers (NS Reed, Section Editor)

New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Melanoma (RJ Sullivan, Section Editor)

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Gynecologic Cancers (NS Reed, Section Editor)

What Is the Best Preoperative Imaging for Endometrial Cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits